Zydus Lifesciences is transitioning from a traditional pharmaceutical company to a more patient-driven organization. The company plans to focus on specialty medicines and biotechnology innovation. It aims to achieve double-digit revenue growth and improved profitability over the next five years. Zydus intends to enhance its oncology franchise and explore partnerships for novel biologics. The expected contributions from discovery-led products will materialize from 2030 onwards, strengthening its market position.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.